Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 2,501–2,600 of 4,628
Zhang, S., Zhou, M., Shao, C., Zhao, Y., Liu, M., Ni, L., Bao, Z., Zhang, Q., Zhang, T., Luo, Q., et al. (2025) · eLife · doi:10.7554/elife.102451.3 · Cited by 13
Zhou, J., Zhou, J., Wang, Y., et al. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.4c06786 · Cited by 8
The Immune Microenvironment: New Therapeutic Implications in Organ Fibrosis
Chen, X., Wu, C. F., Tang, F., Zhou, J., Mo, L., Li, Y., & He, J. (2025) · Advanced Science · doi:10.1002/advs.202505067 · Cited by 15
Maher, T. M., Song, J. W., Kramer, M. R., LANCASTER, L. H., Corte, T. J., Yun, J. H., Kim, K., Cho, J., Sather, L., George, P. M., et al. (2025) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-003038 · Cited by 12
Engelbrecht, E., Kooistra, T., Burg, N. D., Hariri, L. P., Nguyen, T. H., Brazee, P. L., Hla, T., Gochuico, B. R., & Knipe, R. S. (2025) · Pulmonary Circulation · doi:10.1002/pul2.70102 · Cited by 15
Mechanisms on How Matricellular Microenvironments Sustain Idiopathic Pulmonary Fibrosis
Jones, N., Rahar, B., Bernau, K., Schulte, J. J., Campagnola, P. J., & Brasier, A. R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115393 · Cited by 11
Zhao, J., & Zhang, W. Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1619581 · Cited by 13
Liu, H.-J., Diesler, R., Chami, J., Wu, B., Du, H., Jin, Y., Daou, M., Alesi, N., Khabibullin, D., Leroux, C., et al. (2025) · European Respiratory Journal · doi:10.1183/13993003.00084-2025 · Cited by 9
Self-citationCallahan, S. J., Scholand, M. B., Kalra, A., Muelly, M. C., & Reicher, J. J. (2025) · Respiratory Investigation · doi:10.1016/j.resinv.2025.07.021 · Cited by 8
Meersseman, C., Martínez-Besteiro, E., Romain‐Scelle, N., Crestani, B., Marchand-Adam, S., Nunès, H., Wémeau-Stervinou, L., Borie, R., Diesler, R., Valenzuela, C., et al. (2025) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2025.10.004 · Cited by 11
Self-citationJascayd (nerandomilast): a novel PDE4B inhibitor for idiopathic pulmonary fibrosis
Hujjat, S. F. Z., Chandani, H. K., Chandani, D. K., Khan, M. S., & Mahmoud, A. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004290 · Cited by 13
The Patient Journey in Interstitial Lung Disease: Mobility, Independence, and Psychological Burden
Krauss, E., Tello, S., Kuhlewey, D., Mahavadi, P., Scharmer, C., Behr, J., Günther, A., & Huss, G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14248697 · Cited by 9
“Although antifibrotic therapies such as pirfenidone and nintedanib have fundamentally altered the course of fibrotic ILDs by slowing decline in lung function and improving survival, the lived burden remains profound [9,10].”
Adams, G. L., & Hayes, W. (2025) · Pharmaceutical Sciences and Drug Design · doi:10.51847/ie5dkk27c3 · Cited by 8
Luo, M., Al-waqeerah, A., & Gao, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1742761 · Cited by 10
CD248/Endosialin: A Novel Pericyte Target in Renal Fibrosis
Chang-Panesso, M., & Humphreys, B. D. (2015) · The Nephron journals/Nephron journals · doi:10.1159/000440890 · Cited by 8
Kinase profiling in early stage drug discovery: sorting things out
Defert, O., & Boland, S. (2015) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2015.10.002 · Cited by 8
Systemic sclerosis-associated interstitial lung disease
Scallan, C. J., Collins, B. F., & Raghu, G. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000707 · Cited by 12
“Nintedanib reduced the rate of decline in FVC over 1 year among patients with idiopathic pulmonary fibrosis and is approved by the US FDA for this indication [51].”
BackgroundSelf-citationMerino, A. M., Hoogduijn, M. J., Molina‐Molina, M., Arias‐Salgado, E. G., Korevaar, S. S., Baan, C. C., & Montes‐Worboys, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248415 · Cited by 9
“Although numerous therapies have been evaluated in patients with IPF [10], pirfenidone [11] and nintedanib [12] are the only treatments that slow down disease progression [13] but are not fully effective at reducing mortality.”
BackgroundCottin, V., Guéguen, S., Nunès, H., Jouneau, S., Crestani, B., Bonniaud, P., Wémeau-Stervinou, L., Israël‐Biet, D., Reynaud‐Gaubert, M., Gondouin, A., et al. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01961-x · Cited by 10
Self-citationGottlieb, J., Verleden, G. M., Perchl, M., Valtin, C., Vallée, A., Brugière, O., & Bravo, C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260881 · Cited by 9
Singer, D., Bengtson, L. G. S., Conoscenti, C., Anderson, A. J., Brekke, L. N., Shetty, S. S., & de Andrade, J. A. (2022) · Journal of Medical Economics · doi:10.1080/13696998.2022.2054203 · Cited by 8
Rieg, A. D., Suleiman, S., Anker, C., Bünting, N. A., Verjans, E., Spillner, J. W., Kalverkamp, S., von Stillfried, S. F., Braunschweig, T. A., Uhlig, S., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-02101-x · Cited by 10
Antifibrotics and lung transplantation: A Spanish multicentre case‐controlled study
Cuesta, V. M. M., Fernandez, D. I., Ibáñez, S. A., Anguera, G., Iribarnegaray, J. M., Hernández-Rubio, J. C., Mezquida, J. P. R., Pérez-González, V. L., Hernández, R. L., Gafas, A. D. P., et al. (2022) · Respirology · doi:10.1111/resp.14352 · Cited by 9
Cottin, V., Spagnolo, P., Bonniaud, P., Dalon, F., Nolin, M., Kirchgässler, K.-U., Ganse, E. H. V., & Belhassen, M. (2022) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2022.100951 · Cited by 9
Self-citationConnective Tissue Disease Associated Interstitial Lung Disease
Matson, S. M., & Demoruelle, M. K. (2023) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2023.01.005 · Cited by 11
Farrand, E. D., Collard, H. R., Guarnieri, M., Minowada, G., Block, L., Lee, M., & Iribarren, C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0280342 · Cited by 8
Self-citationSwaminathan, A. C., Snyder, L. D., Hong, H., Stevens, S. R., Long, A. S., Yanchenko, E., Qiu, Y., Liu, R., Zhang, H., Fischer, A., et al. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202210-1947oc · Cited by 8
3D-SMGE: a pipeline for scaffold-based molecular generation and evaluation
Xu, C., Liu, R., Huang, S., Li, W., Li, Z., & Luo, H. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad327 · Cited by 8
Uptake of Antifibrotics for Patients with Idiopathic Pulmonary Fibrosis: 2016–2022
Shankar, D. A., Hawkins, F. J., Alysandratos, K., Wilson, K. C., Walkey, A. J., Bosch, N. A., & Law, A. C. (2023) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202308-697rl · Cited by 8
Neighborhood Health and Outcomes in Idiopathic Pulmonary Fibrosis
DeDent, A. M., Collard, H. R., & Thakur, N. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202304-323oc · Cited by 10
Self-citationPulmonary Fibrosis and Diabetes Mellitus: Two coins with the same face
Mendoza‐Marí, Y., Fraix, M. P., & Agrawal, D. K. (2024) · Archives of Internal Medicine Research · doi:10.26502/aimr.0165 · Cited by 16
Predictors of Mortality in Pulmonary Hypertension-Associated Chronic Lung Disease
Pescatore, J., Bittner, M., D’Alonzo, G. E., Weaver, S., & Gayen, S. K. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13123472 · Cited by 8
Huang, P., Wang, X., Cao, Y., Yang, J., Yao, R., Liang, L., Gong, C. B., & Yang, L. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117282 · Cited by 9
Trujillo, G., Regueiro‐Ren, A., Liu, C., Hu, B., Sun, Y. S., Ahangari, F., Fiorini, V., Ishikawa, G., Jumaily, K. A., Khoury, J., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202401-0065oc · Cited by 13
Petersen, A. G., Korntner, S. H., Bousamaki, J., Oró, D., Manresa-Arraut, A., Pors, S. E., Salinas, C. G., Andersen, M. W., Madsen, M. R., Nie, Y., et al. (2024) · Physiological Reports · doi:10.14814/phy2.70077 · Cited by 7
Tang, D. T. Y., Du, Z., Yang, K. S., Bestvater, B. P., Kaplan, J. A., Neubig, M. E., Olen, C. L., Phillips, B., Wang, P., Hudson, T. E., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02090 · Cited by 8
Enomoto, N., Chida, K., Suda, T., Kaida, Y., Taniguchi, M., Azuma, A., Hayashi, H., Ogura, T., Kitamura, H., Yamaguchi, O., et al. (2015) · The Clinical Respiratory Journal · doi:10.1111/crj.12281 · Cited by 8
Self-citationRare (pulmonary) disease day: “feeding the breath, energy for life!”
Harari, S. A., Lau, E., Tamura, Y., Cottin, V., Simonneau, G., & Humbert, M. J. C. (2015) · European Respiratory Journal · doi:10.1183/09031936.00221914 · Cited by 8
Self-citationOrphan drug approvals of 2015: Europe and the United States
Norman, P. (2016) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1167595 · Cited by 8
Hassoun, P. M., & Nathan, S. D. (2016) · European Respiratory Journal · doi:10.1183/13993003.00395-2016 · Cited by 8
Vigeland, C. L., Collins, S. L., Chan‐Li, Y., Hughes, A. H., Oh, M. H., Powell, J. D., & Horton, M. R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163288 · Cited by 10
Ward, K., Spurr, L., Goldman, N. R., et al. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.10.007 · Cited by 8
Improving Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.01.007 · Cited by 9
Self-citationClinical Trials in Idiopathic Pulmonary Fibrosis in the “Posttreatment Era”
Gibson, K. F., & Kass, D. J. (2018) · JAMA · doi:10.1001/jama.2018.6225 · Cited by 8
Futuro del tratamiento farmacológico en fibrosis pulmonar idiopática
Molina‐Molina, M. (2019) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2019.05.008 · Cited by 10
Interstitial Pneumonia with Autoimmune Features
Fischer, A. (2019) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.05.007 · Cited by 9
George, P. M., & Mitchell, J. A. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00330.2019 · Cited by 9
Tahara, M., Oda, K., Yamasaki, K., Kawaguchi, T., Sennari, K., Noguchi, S., Sakamoto, N., Kawanami, T., Mukae, H., & Yatera, K. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0918-3 · Cited by 8
The future of pharmacological treatment in idiopathic pulmonary fibrosis
Molina‐Molina, M. (2019) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2019.05.012 · Cited by 10
A modified scar model with controlled tension on secondary wound healing in mice
Wang, Z., Huang, X., Zan, T., Li, Q., & Li, H. (2020) · Burns & Trauma · doi:10.1093/burnst/tkaa013 · Cited by 11
“Compared to similar diseases, targeted therapies for scar progressed slowly (5, 6).”
BackgroundNintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
Yamasaki, Y., & Kuwana, M. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1777857 · Cited by 8
“The prevalence of diarrhea was higher in SENSCIS than in TOMORROW/INPULSIS, both in the nintedanib and placebo arms, possibly because of coexistence of the underlying lower gastrointestinal involvement of SSc and concomitant use of MMF.”
BackgroundMethodInfluentialTherapeutic potential of targeting kinase inhibition in patients with idiopathic pulmonary fibrosis
Kim, S., Lim, J. H., & Woo, C.-H. (2020) · Journal of Yeungnam Medical Science · doi:10.12701/yujm.2020.00458 · Cited by 8
“Pirfenidone and nintedanib have been recently approved for the treatment of IPF [29-31].”
BackgroundFleming, H., Clifford, S. M., Haughey, A., et al. (2020) · European Radiology Experimental · doi:10.1186/s41747-020-00187-w · Cited by 8
Cottin, V., Bergot, E., BOURDIN, A. A., Nunès, H., Prévôt, G., Wallaert, B., & Marchand-Adam, S. (2021) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2020.100811 · Cited by 10
Self-citationBiener, L., Kruse, J., Tuleta, I., Pizarro, C., Kreuter, M., Birring, S. S., Nickenig, G., & Skowasch, D. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247197 · Cited by 8
“We did observe a significant decline of DLCO and FEV1 predicted in this patient collective, but there was no significant decline of FVC during followup, although FVC is an essential element for the definition of a progressive course of fibrotic lung disease and was the primary endpoint in the INBUILD and INPULSIS tria…”
Evaluation of the efficacy of pirfenidone in progressive chronic hypersensitivity pneumonitis
Shebl, E., & Hamdy, T. (2021) · Egyptian Journal of Bronchology · doi:10.1186/s43168-021-00065-y · Cited by 8
Rheumatological evaluation of patients with interstitial lung disease
Ottaviani, S., Khaleche, S., Borie, R., Debray, M., Dieudé, P., & Crestani, B. (2021) · Scandinavian Journal of Rheumatology · doi:10.1080/03009742.2021.1907945 · Cited by 9
Nishioka, Y., Homma, S. A., Okubo, T., & Azuma, A. (2021) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2021.100832 · Cited by 9
Self-citationProgressive pulmonary fibrosis (PPF)
Duman, D. (2022) · Tuberkuloz ve Toraks · doi:10.5578/tt.20229609 · Cited by 10
Chen, S., Gao, D., Sun, R., et al. (2023) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2023.102202 · Cited by 8
Moodley, Y. P., Corte, T. J., Richeldi, L., & King, T. E. (2015) · Respirology · doi:10.1111/resp.12484 · Cited by 8
Self-citationCritically Ill Patients with Interstitial Lung Disease
Hadley, R. J., & Hyzy, R. C. (2015) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2015.05.012 · Cited by 8
The role of biologics in treatment of connective tissue disease-associated interstitial lung disease
Sharp, C., Dodds, N., Mayers, L., Millar, A., Gunawardena, H., & Adamali, H. I. (2015) · QJM · doi:10.1093/qjmed/hcv007 · Cited by 8
Idiopathic pulmonary fibrosis: combating on a new turf
Raghu, G. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30106-0 · Cited by 8
Self-citationRepositioning compounds from cancer drug discovery to IPF: PI3K inhibition
Staab-Weijnitz, C. A., & Eickelberg, O. (2016) · Thorax · doi:10.1136/thoraxjnl-2016-208680 · Cited by 9
Lung transplantation for high-risk patients with idiopathic pulmonary fibrosis.
Oliveira, N. C. D., Julliard, W. A., Osaki, S., Maloney, J. D., Cornwell, R. D., Sonetti, D. A., & Meyer, K. C. (2016) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 8
Molecular Diagnosis and Precision Therapeutic Approaches for Telomere Biology Disorders
Perona, R., Iarriccio, L., Pintado‐Berninches, L., Rodríguez-Centeno, J., Manguán-García, C., Garcia, E., López‐Ayllón, B. D., & Sastre, L. (2016) · InTech eBooks · doi:10.5772/65353 · Cited by 12
Relaxing Effect of TSU-68, an Antiangiogenic Agent, on Mouse Airway Smooth Muscle
Tan, H., Lei, J., Xue, L., Cai, C., Liu, Q., & Shen, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000475653 · Cited by 8
Current Treatments in the Management of Idiopathic Pulmonary Fibrosis: Pirfenidone and Nintedanib
Hayton, C., & Chaudhuri, N. (2017) · Clinical Medicine Insights Therapeutics · doi:10.1177/1179559x17719126 · Cited by 10
Burgess, A., Goon, K., Brannan, J. D., Attia, J. R., Palazzi, K. L., Oldmeadow, C. J., Corte, T. J., Glaspole, I., Goh, N. S. L., Keir, G. J., et al. (2019) · Respirology · doi:10.1111/resp.13540 · Cited by 9
New radiological diagnostic criteria: impact on idiopathic pulmonary fibrosis diagnosis
Funke-Chambour, M., Guler, S. A., Geiser, T., Christe, A., Heverhagen, J. T., Pöllinger, A., Huber, A. T., & Ebner, L. (2019) · European Respiratory Journal · doi:10.1183/13993003.00905-2019 · Cited by 8
Sodium Arsenite Inhibits Lung Fibroblast Differentiation and Pulmonary Fibrosis
Jiao, H., Song, J., Sun, X., Sun, D. I., & Zhong, M. (2019) · Pharmacology · doi:10.1159/000502536 · Cited by 8
Okuda, R., Hagiwara, E., Katano, T., Ikeda, S., Sekine, A., Kitamura, H., Baba, T., Okudela, K., Ohashi, K., & Ogura, T. (2019) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v36i1.7117 · Cited by 13
Mura, M. (2020) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2020.101987 · Cited by 8
Nemoto, M., Zaizen, Y., Kataoka, K., Kuroda, K., Tabata, K., Bychkov, A., Sumikawa, H., Johkoh, T., Aoshima, M., Kondoh, Y., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245147 · Cited by 9
“Although antifibrotics showed a 50% reduction of FVC decline in 1 year, compared with the placebo group in a phase 3 trial and recent network meta-analysis, the individual response to antifibrotics is unpredictable [6, 10].”
BackgroundResultGeorge, P. M., & Wells, A. U. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1427064 · Cited by 9
Actualités dans les pneumopathies interstitielles idiopathiques en 2016
Debray, M., Borie, R., Danel, C. J., Khalil, A., Majlath, M., & Crestani, B. (2016) · Revue de Pneumologie Clinique · doi:10.1016/j.pneumo.2016.09.001 · Cited by 8
Getting to the core of fibrosis: targeting redox imbalance in aging
Hecker, L., & Thannickal, V. J. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2015.12.45 · Cited by 8
Collagen Biosynthesis in Pulmonary Fibrosis: Unraveling the Metabolic Web
Bernard, K. F. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0350ed · Cited by 9
Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Kim, D. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11454-0 · Cited by 8
Self-citationPanyain, N., Godinat, A., Lanyon‐Hogg, T., et al. (2019) · ChemRxiv · doi:10.26434/chemrxiv.10058429 · Cited by 8
Bouros, D., Daniil, Z., Papakosta, D., Antoniou, K. M., Markopoulou, K., Kolilekas, L., Konstantopoulos, G., Papiris, S., & on behalf of the INDULGE IPF Study Group (2018) · Respiration · doi:10.1159/000487244 · Cited by 7
Ling, S., Kwak, D., & Kim, K. K. (2023) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00066.2023 · Cited by 8
Costa, E., Pedroso, A. R., Matos, R., Rodrigues, M. C., Padrão, E. F. D. S. A. D., Sousa‐Neves, J., & Rolo, R. (2024) · Respiratory Medicine · doi:10.1016/j.rmed.2024.107603 · Cited by 9
Patel, S., Sylvester, K. P., Wu, Z., Rhamie, S., Dickel, P., Maher, T. M., Molyneaux, P. L., Calverley, P. M. A., & Man, W. D. (2024) · ERJ Open Research · doi:10.1183/23120541.00227-2024 · Cited by 8
Chong, W. H., Agrawal, D., Tan, Z. Y., Venkateswaran, S., Tan, A. Y. Y., Tan, C. Y., Ling, N. C. A., & Tay, N. S. W. T. (2024) · Heart & Lung · doi:10.1016/j.hrtlng.2024.07.010 · Cited by 7
Chen, T., Yin, C., Wang, P., Li, Q., Shao, C., Huang, H. F., Song, L., Zhang, W., & Xu, Z. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237170 · Cited by 9
“Therefore, in multicenter clinical And the coexistence of reticular and traction bronchiectasis on HRCT increased the positive predictive value of histopathologically proven UIP [6]. trials of IPF, p-UIP on HRCT was practically diagnosed with IPF without a surgical lung biopsy [7].”
Lyu, W., Wang, H., Ji, T., Liu, L., Chen, H., Fan, L., Zhong, G., Wan, N., Chen, S., Chen, J., et al. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70217 · Cited by 10
Ahmad, A. A., Ghim, M., Kukreja, G., Neishabouri, A., Zhang, Z., Li, J., Salarian, M., Toczek, J., Gona, K. B., Hedayatyanfard, K., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268832 · Cited by 8
Antifibrotic Function of Itaconate-Based Degradable Polyester Materials
Froom, Z. S. C. S., Medd, K., Wheeler, B. P., Osborne, N. D., Rempe, C. N., Woodworth, K. E., Charron, C., & Huyer, L. D. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c02444 · Cited by 10
Kette, S., Reccardini, N., Salton, F., Confalonieri, P., Andrisano, A. G., Chianese, M. I., Nes, A. D., Maggisano, M., Galantino, A., Nicolosi, S., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18030411 · Cited by 8
“In October 2014, the US Food and Drug Administration (FDA) approved two antifi-brotic drugs, pirfenidone and nintedanib, which represent a milestone in the treatment of IPF and are currently used in its management [15–19].”
InfluentialOkuno, D., Akiyama, Y., Sakamoto, N., Tokito, T., Yura, H., Kido, T., Ishimoto, H., Ishimatsu, Y., Takemoto, S., Takazono, T., et al. (2025) · Experimental Cell Research · doi:10.1016/j.yexcr.2025.114584 · Cited by 9
Amin, R., Vaishali, K., Maiya, A. G., Mohapatra, A. K., Acharya, V. K., Dale, M., & Alison, J. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-01877-4 · Cited by 8
Comorbidities’ Effect on IPF: Pathogenesis and Management
Salotti, A., Chianese, M. I., Romallo, A., Nes, A. D., Angoni, D., Galantino, A., Chernovsky, M., Mondini, L., Salton, F., Confalonieri, P., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13061362 · Cited by 9
“Regarding treatment, pivotal trials for both Pirfenidone (ASCEND) and Nintedanib (INPULSIS) included patients with emphysema, and both antifibrotic drugs seem to have a similar effect in CPFE as in IPF alone [44,45].”
Reimagining Fibrosis Research, Outcomes, and Therapeutics Through the Lens of Resolution
Fortier, S. M., Redente, E. F., & Peters-Golden, M. L. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2666-7479 · Cited by 11
Fibroblasts as Immunological Sentinels in Cutaneous Inflammation: A Review
Quan, T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15020556 · Cited by 7
“An-tifibrotic agents targeting TGF-β signaling, including pirfenidone and nintedanib, have shown efficacy in pulmonary fibrosis and are being evaluated for cutaneous fibrosis [187].”
Zhang, H.-Y., Pang, L., Lv, X., Liu, C., & Nan, M.-H. (2020) · Medicine · doi:10.1097/md.0000000000022396 · Cited by 7
Avdeev, S. N., Ananyeva, L. P., Валерьевич, Ж. Е., Zonova, E. V., Клименко, А. А., KONEVA, O. A., Lila, A. M., Pershina, E. S., Стремоухов, А. А., Terpigorev, S. A., et al. (2020) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2020-1-125-128 · Cited by 7
Clinical Overview of Progressive Fibrotic Interstitial Lung Disease
Case, A. H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.858339 · Cited by 8
“The antifibrotic drugs, nintedanib and pirfenidone, both have proven clinical benefit in IPF (60, 61), and both are being studied in non-IPF PF-ILD.”
BackgroundHermansky-Pudlak syndrome: Gene therapy for pulmonary fibrosis
Nieto-Alamilla, G., Behan, M., Hossain, M. S., Gochuico, B. R., & Malicdan, M. C. V. (2022) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2022.08.008 · Cited by 7
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.